PMID- 17258690
OWN - NLM
STAT- MEDLINE
DCOM- 20070606
LR  - 20220318
IS  - 0006-3223 (Print)
IS  - 0006-3223 (Linking)
VI  - 61
IP  - 9
DP  - 2007 May 1
TI  - Topiramate for the treatment of binge eating disorder associated with obesity: a 
      placebo-controlled study.
PG  - 1039-48
AB  - BACKGROUND: In a single-center, placebo-controlled study, topiramate reduced 
      binge eating and weight in patients with binge eating disorder (BED) and obesity. 
      The current investigation evaluated the safety and efficacy of topiramate in a 
      multicenter, placebo-controlled trial. METHODS: Eligible patients between 18 and 
      65 years with >or= 3 binge eating days/week and a body mass index (BMI) between 
      30 and 50 kg/m2 were randomized. RESULTS: A total of 407 patients enrolled; 13 
      failed to meet inclusion criteria, resulting in 195 topiramate and 199 placebo 
      patients. Topiramate reduced binge eating days/week (-3.5 +/- 1.9 vs. -2.5 +/- 
      2.1), binge episodes/week (-5.0 +/- 4.3 vs. -3.4 +/- 3.8), weight (-4.5 +/- 5.1 
      kg vs. .2 +/- 3.2 kg), and BMI (-1.6 +/- 1.8 kg/m2 vs. .1 +/- 1.2 kg/m2) compared 
      with placebo (p < .001). Topiramate induced binge eating remission in 58% of 
      patients (placebo, 29%; p < .001). Discontinuation rates were 30% in each group; 
      adverse events (AEs) were the most common reason for topiramate discontinuation 
      (16%; placebo, 8%). Paresthesia, upper respiratory tract infection, somnolence, 
      and nausea were the most common AEs with topiramate. CONCLUSIONS: This 
      multicenter study in patients with BED associated with obesity demonstrated that 
      topiramate was well tolerated and efficacious in improving the features of BED 
      and in reducing obesity.
FAU - McElroy, Susan L
AU  - McElroy SL
AD  - Psychopharmacology Research Program, Department of Psychiatry, University of 
      Cincinnati College of Medicine, Cincinnati, Ohio 45267-0559, USA. 
      susan.mcelroy@uc.edu
FAU - Hudson, James I
AU  - Hudson JI
FAU - Capece, Julie A
AU  - Capece JA
FAU - Beyers, Karen
AU  - Beyers K
FAU - Fisher, Alan C
AU  - Fisher AC
FAU - Rosenthal, Norman R
AU  - Rosenthal NR
CN  - Topiramate Binge Eating Disorder Research Group
LA  - eng
SI  - ClinicalTrials.gov/NCT00210808
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20070129
PL  - United States
TA  - Biol Psychiatry
JT  - Biological psychiatry
JID - 0213264
RN  - 0 (Anti-Obesity Agents)
RN  - 0H73WJJ391 (Topiramate)
RN  - 30237-26-4 (Fructose)
SB  - IM
MH  - Adult
MH  - Anti-Obesity Agents/adverse effects/*therapeutic use
MH  - Body Mass Index
MH  - Bulimia Nervosa/complications/*drug therapy/psychology
MH  - Double-Blind Method
MH  - Female
MH  - Fructose/adverse effects/*analogs & derivatives/therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Obesity/*drug therapy/etiology/psychology
MH  - Psychiatric Status Rating Scales
MH  - Topiramate
MH  - Treatment Outcome
EDAT- 2007/01/30 09:00
MHDA- 2007/06/07 09:00
CRDT- 2007/01/30 09:00
PHST- 2006/06/14 00:00 [received]
PHST- 2006/08/10 00:00 [revised]
PHST- 2006/08/11 00:00 [accepted]
PHST- 2007/01/30 09:00 [pubmed]
PHST- 2007/06/07 09:00 [medline]
PHST- 2007/01/30 09:00 [entrez]
AID - S0006-3223(06)01009-2 [pii]
AID - 10.1016/j.biopsych.2006.08.008 [doi]
PST - ppublish
SO  - Biol Psychiatry. 2007 May 1;61(9):1039-48. doi: 10.1016/j.biopsych.2006.08.008. 
      Epub 2007 Jan 29.